Pexastimogene devacirepvec
As of the edition of 20 October 2026, Pexastimogene devacirepvec is a gene: stopped in 2021; acts on CSF2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Gene
- Registered trials
- 14, 3 stopped early
- Disease areas
- Cancer; Digestive system; Infections; Pregnancy and women's health; Urinary and reproductive; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Pexastimogene devacirepvec.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF2 | Granulocyte-macrophage colony-stimulating factor | P04141 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 8 | 4 | 0 | 3 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jennerex Biotherapeutics | Lead sponsor of trials | 2007 to now |
| SillaJen | Lead sponsor of trials | 2015 to now |
| Transgene | Lead sponsor of trials | 2017 to now |